DGAP-News: Laxxon Medical
/ Schlagwort(e): Sonstiges
NEW YORK, NY / ACCESSWIRE / January 7, 2022 / Laxxon Medical Corporation announced today that management will conduct one-on-one meetings at the 24th Annual Needham Growth Conference, which will be held virtually from Jan 10-14, 2022. About Laxxon Medical Corporation Laxxon Medical holds the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture and commercialization of pharmaceutical dosage forms. ?With Laxxon Medical's innovative SPID(R)-Technology (Screen Printing Innovational Drug Technology), it is possible for the first time to develop oral, transdermal and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients within the printed units yielding dosage forms with tailored release of active ingredients. To learn more about Laxxon Medical's disruptive 3D screen printing technology, visit www.laxxonmedical.com. Contact:
Frances Hoggard, Public Relations Manager SOURCE: Laxxon Medical Corporation
07.01.2022 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch DGAP - ein Service der EQS Group AG. |
| Sprache: | Deutsch |
| Unternehmen: | Laxxon Medical |
| 135 E 57th St., 14th Floor | |
| 10022 New York | |
| Vereinigte Staaten von Amerika | |
| EQS News ID: | 1266336 |
| Ende der Mitteilung | DGAP News-Service |
1266336 07.01.2022
